Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry.
Fabrizio D'AscenzoDario CelentaniAlessandro BrustioAlberto GrossoSergio Raposeiras-RoubínEmad Abu-AssiJose Paulo Simao HenriquesJorge SaucedoJosé Ramón González-JuanateyStephen B WiltonWouter J KikkertIván Nuñez-GilAlbert Ariza-SoleXiantao SongDimitrios AlexopoulosChristoph LiebetrauTetsuma KawajiZenon HuczekShao-Ping NieToshiharu FujiiLuis CorreiaMasa-Aki KawashiriJosé María García-AcuñaDanielle SouthernEmilio AlfonsoBelén TerolAlberto GarayDongfeng ZhangYalei ChenIoanna XanthopoulouNeriman OsmanHelge MöllmannHiroki ShiomiMichal KowaraKrzysztof FilipiakXiao WangYan YanJing-Yao FanYuji IkariTakuya NakahayshiKenji SakataMasakazu YamagishiOliver KalpakSasko KedevClaudio MorettiMaurizio D'AmicoFiorenzo GaitaPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2018)
BB therapy was related to 1-year lower risk of all-cause mortality, independently from completeness of revascularization, admission diagnosis, age and ejection fraction. Randomized controlled trials for patients treated with PCI for ACS should be performed.
Keyphrases
- acute coronary syndrome
- ejection fraction
- percutaneous coronary intervention
- antiplatelet therapy
- aortic stenosis
- acute myocardial infarction
- st segment elevation myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- st elevation myocardial infarction
- randomized controlled trial
- atrial fibrillation
- emergency department
- angiotensin converting enzyme
- heart failure
- stem cells
- left ventricular
- coronary artery bypass
- angiotensin ii